Back to results
US 2014/0235828 A1Published application
Gram-positive bacteria specific binding compounds
AssigneesAimm Therapeutics B.V., Genentech, Inc.
InventorsTim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
Life of this patent
Estimating the term…
Abstract
The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
Claims43
An isolated antibody comprising:
- (a) a heavy chain CDR1 sequence RFAMS (SEQ ID NO:1), and
- (b) a heavy chain CDR2 sequence SINNGNNPYYARSVQY (SEQ ID NO:2), and
- (c) a heavy chain CDR3 sequence DHPSSGWPTFDS (SEQ ID NO:3).
An isolated antibody comprising:
- (a) a light chain CDR1 sequence RASENVGDWLA (SEQ ID NO:4), and
- (b) a light chain CDR2 sequence KTSILES (SEQ ID NO:5), and
- (c) a light chain CDR3 sequence having at least 88% identity to QHYXRFPYT, wherein X is any amino acid.
Dependencies are inferred from the claim text.